treatment abandonment
Recently Published Documents


TOTAL DOCUMENTS

84
(FIVE YEARS 45)

H-INDEX

11
(FIVE YEARS 3)

2022 ◽  
Vol 11 (1) ◽  
pp. e35511124615
Author(s):  
Vânia Maria de Carvalho Diniz ◽  
Bruna Miranda Januário ◽  
João Paulo da Silva Teixeira ◽  
Manoel José de Lima Neto ◽  
José Israel Guerra Junior ◽  
...  

Introduction: Mental disorders are more and more frequent. In Brazil, primary care makes possible the population's first encounter with mental care, having medicines as one of the main therapeutic applied resources, which are made available in different ways, including the municipal primary pharmacy. Psychotropic drugs, such as anxiolytics, act on these mental disorders, improving the quality of life and providing freedom to the individual, however, their use irrationally and for a prolonged period of time causes harm to those who use them. Objective: To know the aspects surrounding the consumption of anxiolytic drugs, as well as to identify individual and collective characteristics of the participants that lead to their use. Methodology: Cross-sectional descriptive research with a quali-quantitative approach, carried out with prescriptions that contained anxiolytics and questionnaires answered by patients treated at the basic pharmacy in the city of Flores - PE. Results: The female gender, age group over 41 years, low education, presence of children and marriage were related to the increase in the use of anxiolytics, in addition, the emergence of effects caused by treatment abandonment, interactions regarding the use of plants or more of a drug with anxiolytics and the errors of gifts in prescriptions had high rates. Conclusion: The delineation of the profile of individuals who use anxiolytics as therapy provides the creation of policies at specific groups in order to reduce the therapy with them, in addition, knowledge of the main errors in prescriptions and the presence of interactions ensures a better treatment success.


Molecules ◽  
2022 ◽  
Vol 27 (1) ◽  
pp. 319
Author(s):  
Paulo A. F. Pacheco ◽  
Maria M. M. Santos

Human protozoan diseases represent a serious health problem worldwide, affecting mainly people in social and economic vulnerability. These diseases have attracted little investment in drug discovery, which is reflected in the limited available therapeutic arsenal. Authorized drugs present problems such as low efficacy in some stages of the disease or toxicity, which result in undesirable side effects and treatment abandonment. Moreover, the emergence of drug-resistant parasite strains makes necessary an even greater effort to develop safe and effective antiparasitic agents. Among the chemotypes investigated for parasitic diseases, the indole nucleus has emerged as a privileged molecular scaffold for the generation of new drug candidates. In this review, the authors provide an overview of the indole-based compounds developed against important parasitic diseases, namely malaria, trypanosomiasis and leishmaniasis, by focusing on the design, optimization and synthesis of the most relevant synthetic indole scaffolds recently reported.


2021 ◽  
Vol 7 ◽  
pp. 1-10
Author(s):  
Jamylle Souza Rodrigues ◽  
Marco Aurélio De Oliveira Góes

Introduction: Tuberculosis (TB) represents a challenge that go through the history of mankind. The monitoring in the Primary Health Care (PHC) consists in an important mechanism of accomplishment of the policies on TB, since it provides greater longitudinal care relationship (longitudinality) and closeness to the infected individual. Objective: To analyze TB cases attended by the PHC in Sergipe. Outline: It was performed a retrospective cohort of the TB cases attended by the PHC in Sergipe between 2014 and 2018. Results: 2,172 TB cases attended by the PHC in Sergipe were included, of which 283 (13.0%) abandoned the treatment, 1813 (83.5%) progressed to cure and 76 (3.5%) to death. The factors associated with treatment abandonment were: male, age range of 20 to 29 years, alcoholics, people with diabetes mellitus and persons deprived of liberty. In relation to the mortality, higher rates were found in: male, age range of 70 years and above, illiterate and people with diabetes mellitus. Implications: Conditions of social vulnerability and comorbidities impacted mortality, as well as abandonment of TB treatment.


Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5862
Author(s):  
Junyang Zhao ◽  
Qiyan Li ◽  
Zhao Xun Feng ◽  
Jianping Zhang ◽  
Songyi Wu ◽  
...  

Intraocular surgery is tabooed in retinoblastoma management, due to the concern of lethal extraocular spread. We reviewed the outcomes of consecutive children with intraocular retinoblastoma diagnosed at 29 Chinese centers between 2012–2014. We compared the outcomes of three categories of treatment: eye salvage including tylectomy (Group I), eye salvage without tylectomy (Group II), and primary enucleation (Group III). A total of 960 patients (1243 eyes) were diagnosed: 256 in Group I, 370 in Group II, and 293 in Group III; 41 patients abandoned treatment upfront. The estimated 5-year overall survivals (OS) were, for Group I, 94%, for Group II 89%, and for Group III 95%. The estimated 5-year disease-specific survivals (DSS) were, for Group I, 96%, for Group II 90%, and for Group III 95%. Patients in Group I had a significantly higher 5-year DSS than patients in Group II (p = 0.003) and not significantly different than patients in Group III (p = 0.367). Overall survival was not compromised by the inclusion of tylectomy in eye salvage therapy compared to eye salvage without tylectomy or primary enucleation. Disease-specific survival was better when tylectomy was included in eye salvage treatments. Tylectomy as part of multimodal treatment may contribute to the care of retinoblastoma patients with chemotherapy-resistant tumor, eyes with concomitant ocular complications, or at the risk of treatment abandonment.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4102-4102
Author(s):  
Andres Gomez-De Leon ◽  
Ana Varela-Constantino ◽  
Perla R. R. Colunga-Pedraza ◽  
Alexia Sánchez-Arteaga ◽  
Valeria García-Zárate ◽  
...  

Abstract Introduction Pediatric inspired regimens can achieve good outcomes in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) by delivering intense non-myelosuppressive chemotherapy and are considered standard. Experience with the implementation of these regimens outside of academic centers in high-income countries is limited. Furthermore, Mexican patients (with "hispanic ethnicity") have increased risk for relapse and treatment related complications. Objectives Primary objective: to determine 2-year overall survival (OS) and event-free survival (EFS). Secondary objectives: to determine the impacts of treatment abandonment and measurable residual disease (MRD) on outcomes, and to compare treatment costs with a widely used standard regimen in the United States. Patients and Methods Consecutive patients 16-45 years diagnosed with Ph-negative B-cell acute lymphoblastic leukemia after 2016 were included. The salient features of our modified-BFM regimen include the use mitoxantrone, E. coli L-asparaginase, without systemic cytarabine or high dose methotrexate designed to be delivered entirely in an outpatient basis for maximum affordability (Table 1), given that we treat an uninsured population that must cover their own treatment costs out of pocket. Genetic risk assessment was limited to BCR/ABL. Thereafter, relapse risk assessment was based exclusively on "next generation" flow cytometry measurable residual disease (MRD) after consolidation, with a planned allogeneic transplant for MRD-positive patients (≥0.001%). Treatment abandonment was defined as a missed ≥14-day period during intensive treatment or ≥1 month during maintenance. Statistical analysis was performed as intent-to-treat. Lastly, drugs included in our protocol were compared to those of CALGB 10403 with current local pricing in USD. Results Ninety-one AYAs have been treated, 47 women and 44 men, with a median age of 21 years (range, 15-45), mostly with a good functional capacity and no comorbidities (ECOG≤2: 92.1%; HCT-Ci 0-1: 97.8%); 43.8% of patients had ≥30x10 9/L white blood cells at diagnosis and 31.7% had grade ≥1 obesity. Notable grade ≥3 adverse events during induction were infections/neutropenic fever (35.6%),hepatotoxicity (11%) and thrombosis/bleeding (8.1%) with 44.3% eventually requiring hospitalization. Induction related mortality was 11%. Only n=3 were refractory to induction and the remainder assessed achieved complete remission (n=63; 95.5%) with a median follow-up of 15 months (range, 0.9-50.1). N=29 received induction and consolidation entirely on an outpatient basis, ulterior hospitalizations during therapy were rare. Treatment abandonment was common (n=24; 26.4%) usually during induction (n=8; 32%) or consolidation (n=12; 48%) and mostly related to unaffordability. For the same reason, transfers to social security healthcare systems were also frequent (n=19; 20.9%). Most patients assessed were MRD negative (n=38; 74.5%) Early relapse incidence was 32.9%; 44.4% in MRD-positive and 27.5% in MRD-negative patients (p=0.43). OS at 24 months was 61.5% (95% CI 47-73%) and EFS 49.8% (95% CI 37-62%) with excellent outcomes for MRD-negative patients (Figure 1, Panels A and B). Treatment abandonment and MRD positivity were the only independent predictors of mortality in a multivariate analysis (HR 7.8 [95% CI 2.8-21.9] and HR 4.5 [95% CI 1.4-14], respectively). Lastly, the total cumulative price for medications included in our regimen was calculated at $16,750 vs. $36,061 USD in CALGB 10403, representing a cost reduction of 53.5%. Conclusions The treatment of Hispanic ALL patients with our regimen has shown promising outcomes at a reduced cost for patients. Genetic risk assessment, induction mortality, treatment abandonment and lack of access to novel therapies for MRD positive patients remain the main barriers for improving outcomes further. Figure 1 Figure 1. Disclosures Gomez-De Leon: Novartis: Honoraria; ASH: Research Funding; Sanofi: Honoraria; Abbvie: Honoraria. González López: JANSSEN: Honoraria; AMGEN: Honoraria. Gomez-Almaguer: Roche: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Bristol-Myers-Squibb: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau.


2021 ◽  
Author(s):  
George Chagaluka ◽  
Glenn Mbah Afungchwi ◽  
Lisa Landman ◽  
Festus Njuguna ◽  
Peter Hesseling ◽  
...  

2021 ◽  
Vol 22 (9) ◽  
pp. 2873-2877
Author(s):  
Czar Louie Gaston ◽  
Kathleen Taleon ◽  
Ken Barsales ◽  
Cesar Dimayuga ◽  
Jochrys Estanislao ◽  
...  

2021 ◽  
pp. e20210018
Author(s):  
Pedro Daibert de Navarro1,2 ◽  
João Paulo Amaral Haddad3 ◽  
Juliana Veiga Costa Rabelo1 ◽  
Claudia Hermínia de Lima e Silva4 ◽  
Isabela Neves de Almeida2,5 ◽  
...  

Objective: Evaluate the impact of the instrument of the "Stratification by Degree of Clinical Severity and Abandonment Risk of Tuberculosis Treatment" (SRTB) on the tuberculosis outcome. Methods: This study was a pragmatic clinical trial involving patients with a confirmed diagnosis of tuberculosis treated at one of the 152 primary health care units in the city of Belo Horizonte, Brazil, between May of 2016 and April of 2017. Cluster areas for tuberculosis were identified, and the units and their respective patients were divided into intervention (use of SRTB) and nonintervention groups. Results: The total sample comprised 432 participants, 223 and 209 of whom being allocated to the nonintervention and intervention groups, respectively. The risk of treatment abandonment in the nonintervention group was significantly higher than was that in the intervention group (OR = 15.010; p < 0.001), regardless of the number of risk factors identified. Kaplan-Meier curves showed a hazard ratio of 0.0753 (p < 0.001). Conclusions: The SRTB instrument was effective in reducing abandonment of tuberculosis treatment, regardless of the number of risk factors for that. This instrument is rapid and easy to use, and can be adapted to different realities. Its application showed characteristics predisposing to a non-adherence to the treatment and established bases to mitigate its impact.


2021 ◽  
Vol 2 (4) ◽  
pp. 5505-5512
Author(s):  
Bernat-Noël Tiffon Nonis

Se ilustra un caso de asesinato perpetrado por un sujeto afecto de esquizofrenia paranoide y, por cuyo momento de perpetrarse los hechos, presentaba una crisis psicótica aguda en ausencia de medicación antipsicótico por abandono del tratamiento. Se describe la fenomenología clínico-sintomatológica del perpetrador y del tipo de contenido de pensamiento psicótico-paranoide que mostraba al momento de celebrarse las entrevistas psicológicos-forenses.   A case of murder perpetrated by a subject affected by paranoid schizophrenia and, at the time of the perpetration, presenting an acute psychotic crisis in the absence of antipsychotic medication due to treatment abandonment, is illustrated. The clinical-symptomatological phenomenology of the perpetrator and the type of psychotic-paranoid thought content he showed at the time of the psychological-forensic interviews are described.


Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3646
Author(s):  
Junyang Zhao ◽  
Zhaoxun Feng ◽  
Brenda L. Gallie

Treatment abandonment is a leading cause of death in children with retinoblastoma worldwide. We studied children who abandoned treatment upfront at diagnosis to delineate the natural history of untreated retinoblastoma. Studied were children who received no treatment, diagnosed between 2007 and 2017 at 29 Chinese centers. Data were retrospectively collected from medical chart reviews and interviews with each patient’s family. During the study period, 44 children received no treatment after diagnosis of retinoblastoma. Clinical or radiologic evidence of orbital extension was available for 25 children, and radiologic evidence of systemic metastasis was available for 12 children. Median times from diagnosis of intraocular tumor to orbital disease was 13.7 months, orbital disease to metastasis was 2.6 months, and metastasis to death was 2.0 months. Children with brain metastasis had shorter survival than those with metastasis to other sites (median 1.0 vs. 3.1 months; p = 0.015). Overall, 36% of patients died within 12 months of diagnosis, 77% within 24 months, 95% within 36 months and 100% within 48 months. While multiple factors influence refusal of treatment, insights into the natural history of retinoblastoma derived from real-world evidence can inform clinicians and parents that retinoblastoma is life-threatening and encourage urgent treatment at diagnosis.


Sign in / Sign up

Export Citation Format

Share Document